Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Trial Profile

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Nirogacestat (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RHEA
  • Most Recent Events

    • 29 Oct 2015 Status changed from recruiting to withdrawn prior to enrolment as reported ClinicalTrials.gov record.
    • 07 Jun 2015 Status changed from not yet recruiting to recruiting as reported ClinicalTrials.gov record.
    • 25 May 2015 Planned initiation date changed from 1 Mar 2015 to 1 May 2015 as reported ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top